NEW YORK (GenomeWeb) – Protea Biosciences Group said today that it has undertaken a collaborative research effort with Memorial Sloan Kettering Cancer Center and the Dana-Farber Cancer Institute with an initial focus on lung cancer.

The partners will use Protea's next generation LAESI (Laser Ablation Electrospray Ionization) direct molecular imaging technology to analyze cancer cells. Protea said they will "generate molecular data profiles of cancer cells in tissue and biofluids to improve the understanding of a cancer's origin."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.